Thank you CARB-X for the continued support of Vedanta Biosciences, Inc. antibacterial programs. This partnership helps advance VE707 into IND in preparation for a first-in-human study in prevention of MDRO infections.
Vedanta Biosciences, Inc.
Biotechnology Research
Cambridge, MA 10,292 followers
Pioneering rational design of drugs made of defined bacteria consortia that are essential dwellers of the gut ecosystem.
About us
The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology
- Website
-
http://www.vedantabio.com
External link for Vedanta Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Specialties
- human microbiome and mucosal immunology
Locations
-
Primary
Get directions
19 Blackstone Street
Cambridge, MA 02139, US
Employees at Vedanta Biosciences, Inc.
Updates
-
Vedanta Biosciences, Inc. reposted this
Colorcon Ventures, the corporate venture fund of Colorcon® Inc., has invested in Vedanta Biosciences, Inc., a clinical stage life sciences company that designs and manufactures proprietary, orally delivered bacterial therapies. Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Vedanta Biosciences is aligned with Colorcon Ventures’ interest in emerging classes of drugs for oral administration. The company’s unique approach within microbial therapeutics has the potential to offer safer and more efficacious treatments for a number of indications. Vedanta has also revolutionized the manufacturing of defined bacterial consortia at scale, which adds significant value to the sector. We look forward to supporting Vedanta Biosciences as they realize the full potential of their platform technology.” Press Release ➡️https://hubs.ly/Q02lRXmx0
-
-
Elle Noble and I spoke about (1) what to look for when recruiting talent into a startup, and a subgenre: what to look for when recruiting executives into a startup and (2) the microbiome field (what indications best lend themselves to microbiome therapeutics, and is there any merit to microbiome diagnostics?). 1'05" – what is the scope of potential microbiome therapeutics? What indications lend themselves to being treated through microbiome therapy, and are there any future microbiome blockbusters? 6’ 23” – How do you deem a patient suitable for a microbiome therapeutic, when each person has a different make-up of bacteria? 9’05” – When recruiting, what quality do you think makes a candidate and exceptional hire? 17’36” – what quality makes a candidate an exceptional hire for an executive position in a startup?
Microbiome Miracles | Bernat Olle, CEO of Vedanta Biosciences | X4 Talks
https://www.youtube.com/
-
Vedanta has dosed the first patient in a Phase 2 Clinical trial of VE202 for the treatment of ulcerative colitis and received Fast Track Designation for this program https://lnkd.in/eKc9nz8R VE202 is an orally administered, investigational live biotherapeutic product consortium consisting of 16 strains of bacteria, rationally selected to induce immune tolerance in the gut, reverse gut microbiota abnormalities common in IBD, and strengthen the epithelial barrier. Results describing the biology and candidate selection of VE202 were previously published in Nature https://lnkd.in/e8p-rycp https://lnkd.in/eMmN8fxg and Amanda Prince will be presenting additional data at the Keystone Symposia “Mechanisms of Microbiota-Immune Interactions” In a Phase 1 study in NHV, VE202 strains colonized robustly, in both a dose- and duration-dependent manner and accelerated conversion of 1o bile acids to immunomodulating 2o bile acids that protect against intestinal inflammation compared to PBO. VE202 was also well tolerated COLLECTiVE202 https://lnkd.in/ecgJTyp2 is a double-blind, placebo-controlled, randomized clinical trial that is being conducted at sites in the US and EU. It is enrolling 100 patients with mild-to-moderate UC between the ages of 18 and 75 years.
-
-
This year we brought the Vedanta Biosciences, Inc. summer party to the Museum of Science. Some friendly competition, food, and the Boston/Cambridge skylines made for a memorable day!
-
-
Host, Business of Biotech Podcast and Chief Editor, Bioprocess Online, Life Science Connect
This week's episode of the #businessofbiotech is now available, bringing you two perspectives on a #biopharma #venturecapital deal with Vedanta Biosciences, Inc. Bernat Olle and K2 HealthVentures' Parag Shah. Check it out here: https://lnkd.in/eCK9Wwya The Business of Biotech is produced by Bioprocess Online, part of the Life Science Connect family, with support from Cytiva.
-
The Vedanta Biosciences, Inc. team ran the JP Morgan Corporate Challenge once again, with standout performances across the board.
-